ATE509636T1 - Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität - Google Patents

Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität

Info

Publication number: ATE509636T1
Authority: AT; Austria
Prior art keywords: compound; combination; cholinesterase inhibitor; receptor affinity; active substance
Prior art date: 2006-06-23

Application number

AT07765553T

Other languages

English (en)

Inventor

Xavier Codony-Soler

Helmut Heinrich Buschmann

Original Assignee

Esteve Labor Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2007-06-22

Publication date

2011-06-15

2007-06-22 Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE509636T1 publication Critical patent/ATE509636T1/de

Links

108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
229940122041 Cholinesterase inhibitor Drugs 0.000 title abstract 2
239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
239000013543 active substance Substances 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)

AT07765553T 2006-06-23 2007-06-22 Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität ATE509636T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06384012		2006-06-23
PCT/EP2007/056234 WO2007147883A1 (en)	2006-06-23	2007-06-22	Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity

Publications (1)

Publication Number	Publication Date
ATE509636T1 true ATE509636T1 (de)	2011-06-15

Family

ID=37302308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07765553T ATE509636T1 (de)	2006-06-23	2007-06-22	Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität

Country Status (10)

Country	Link
US (1)	US20100120747A1 (de)
EP (1)	EP2040755B1 (de)
JP (1)	JP2009541423A (de)
CN (1)	CN101500611A (de)
AT (1)	ATE509636T1 (de)
CA (1)	CA2658959A1 (de)
ES (1)	ES2366958T3 (de)
MX (1)	MX2008015996A (de)
PT (1)	PT2040755E (de)
WO (1)	WO2007147883A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008087123A2 (en) *	2007-01-16	2008-07-24	Solvay Pharmaceuticals B.V.	Use of 5-ht6 antagonists to prevent relapse into addiction
EP1953153A1 (de) *	2007-01-31	2008-08-06	Laboratorios del Dr. Esteve S.A.	Heterocyclyl-substituierte Sulfonamide für die Behandlung von Wahrnehmungsstörungen bzw. Ernährungserkrankungen
WO2009022346A2 (en) *	2007-08-14	2009-02-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Phenyl carbamates for treating gastrointestinal inflammation
EP2254564A1 (de) *	2007-12-12	2010-12-01	Glaxo Group Limited	Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
RU2384581C2 (ru) *	2008-05-07	2010-03-20	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2391343C1 (ru) *	2008-09-24	2010-06-10	Андрей Александрович Иващенко	ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2011082400A2 (en) *	2010-01-04	2011-07-07	President And Fellows Of Harvard College	Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN101953829A (zh) *	2010-08-03	2011-01-26	中国人民解放军第二军医大学	欧芹素乙在制备抗肿瘤药物中的应用
AU2012321345B2 (en)	2011-10-03	2016-03-17	The University Of Utah Research Foundation	Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US9084800B2 (en) *	2011-11-07	2015-07-21	Natreon, Inc.	Indolealkylamino-withasteroid conjugates and method of use
EP2647377A1 (de)	2012-04-06	2013-10-09	Sanofi	Verwendung eines H3-Rezeptorantagonisten zur Behandlung von Morbus Alzheimer
JO3459B1 (ar)	2012-09-09	2020-07-05	H Lundbeck As	تركيبات صيدلانية لعلاج مرض الزهايمر
CN105764510A (zh) *	2013-09-09	2016-07-13	赛诺菲	H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
HRP20190219T1 (hr) *	2013-11-26	2019-03-22	The Children's Medical Center Corporation	Spojevi za tretman pretilosti i postupci za njihovu uporabu
CN103948036B (zh) *	2014-05-13	2015-11-25	陈金杰	一种抗神经衰弱的保健品及其应用
KR20180021693A (ko) *	2015-05-07	2018-03-05	엑소반트 사이언시즈 게엠베하	신경퇴행성 질환을 치료하는 조성물 및 방법
CN104983715B (zh) *	2015-05-19	2017-11-17	北京联合大学	一种盐酸小檗碱微囊的制备方法
HK1245660A1 (zh)	2015-06-12	2018-08-31	Axovant Sciences Gmbh	有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en)	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
KR101781060B1 (ko)	2016-02-23	2017-09-25	주식회사 레스코퍼레이션	허혈성 뇌졸중의 치료 및 예방용 약학 조성물
PT3448430T (pt) *	2016-04-26	2023-07-11	H Lundbeck As	Uso de inibidores da acetilcolinesterase e idalopirdina para reduzir quedas em doentes com doença de parkinson
NZ748280A (en)	2016-05-18	2020-07-31	Suven Life Sciences Ltd	Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
CA3089695A1 (en) *	2018-02-19	2019-08-22	Natreon, Inc.	Synergistic combinations of urolithins a and b for improving cognitive capacity or cognitive function
PT3860998T (pt)	2018-10-05	2024-04-02	Annapurna Bio Inc	Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
CN109439705B (zh) *	2018-12-05	2021-10-01	广州中医药大学(广州中医药研究院)	一种柳珊瑚酸的微生物制备方法
DK4426434T3 (da)	2021-11-02	2025-11-10	Flare Therapeutics Inc	Pparg inverse agonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999001111A1 (en) *	1997-07-02	1999-01-14	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
US6193993B1 (en) *	1998-03-03	2001-02-27	Eisai Co., Ltd.	Suppository containing an antidementia medicament
US7034029B2 (en) *	2000-11-02	2006-04-25	Wyeth	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1411925A1 (de) *	2001-08-03	2004-04-28	PHARMACIA & UPJOHN COMPANY	5-arylsulfonyl-indole mit 5-ht6 rezeptor-affinität
US6906095B2 (en) *	2002-05-10	2005-06-14	Wyeth	Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6951881B2 (en) *	2002-05-10	2005-10-04	Wyeth	(1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6875771B2 (en) *	2002-07-26	2005-04-05	Bristol-Myers Squibb Company	Pyridopyrimidine derivatives as 5-HT6 antagonists
EP1562918B1 (de) *	2002-11-08	2008-01-16	F. Hoffmann-La Roche Ag	Substituierte benzoxazinones und ihre verwendung
PL378120A1 (pl) *	2003-02-14	2006-03-06	Wyeth	Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
ES2228268B1 (es) *	2003-07-30	2006-07-01	Laboratorios Del Dr. Esteve, S.A.	Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
TW200524864A (en) *	2003-11-10	2005-08-01	Wyeth Corp	Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
EP1632491A1 (de) *	2004-08-30	2006-03-08	Laboratorios Del Dr. Esteve, S.A.	Substituierte indol-verbindungen und deren verwendung als modulatoren des 5-ht6 rezeptors
PE20071143A1 (es) *	2006-01-13	2008-01-20	Wyeth Corp	Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6

2007
- 2007-06-22 WO PCT/EP2007/056234 patent/WO2007147883A1/en not_active Ceased
- 2007-06-22 CN CNA2007800251169A patent/CN101500611A/zh active Pending
- 2007-06-22 US US12/305,516 patent/US20100120747A1/en not_active Abandoned
- 2007-06-22 MX MX2008015996A patent/MX2008015996A/es active IP Right Grant
- 2007-06-22 JP JP2009517134A patent/JP2009541423A/ja active Pending
- 2007-06-22 CA CA002658959A patent/CA2658959A1/en not_active Abandoned
- 2007-06-22 PT PT07765553T patent/PT2040755E/pt unknown
- 2007-06-22 ES ES07765553T patent/ES2366958T3/es active Active
- 2007-06-22 EP EP07765553A patent/EP2040755B1/de not_active Not-in-force
- 2007-06-22 AT AT07765553T patent/ATE509636T1/de active

Also Published As

Publication number	Publication date
MX2008015996A (es)	2009-01-20
JP2009541423A (ja)	2009-11-26
US20100120747A1 (en)	2010-05-13
CN101500611A (zh)	2009-08-05
EP2040755A1 (de)	2009-04-01
CA2658959A1 (en)	2007-12-27
PT2040755E (pt)	2011-07-08
EP2040755B1 (de)	2011-05-18
ES2366958T3 (es)	2011-10-27
WO2007147883A1 (en)	2007-12-27
HK1132175A1 (en)	2010-02-19

Legal Events

Date

Code

Title

Description

2012-01-15

UEP

Publication of translation of european patent specification

Ref document number: 2040755

Country of ref document: EP

Publication	Publication Date	Title
PT2040755E (pt)	2011-07-08	Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
MX2009002903A (es)	2009-04-01	Combinacion de un ligando del receptor nmda y un compuesto con afinidad por el receptor 5-ht6.
ATE515260T1 (de)	2011-07-15	Stabile nanokapselsysteme für die verabreichung von wirkstoffen
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2012000887A1 (es)	2012-10-19	Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
WO2007098474A8 (en)	2008-11-06	Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
WO2007109330A3 (en)	2007-11-22	S1p receptor modulating compounds
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
UA98839C2 (en)	2012-06-25	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0414581C1 (pt)	2021-05-25	composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
ATE488232T1 (de)	2010-12-15	P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
UY32238A (es)	2010-01-05	Agonistas de los receptores de la melanocortina
EA201101118A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CR10344A (es)	2008-10-29	2-(piridin)-2-il)-pirimidinas como fungicidas
CL2007001838A1 (es)	2008-02-08	Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
BRPI0717369A2 (pt)	2014-10-07	Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0911772A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso do composto.
EA200702529A1 (ru)	2008-04-28	Фунгицидная комбинация биологически активных веществ
PA8814801A1 (es)	2009-09-17	Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
CL2009000904A1 (es)	2010-04-30	Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2008000093A1 (es)	2008-08-22	Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
MX2010003591A (es)	2010-04-21	Capa protectora mecanica para formas de dosificacion solidas.
ATE409040T1 (de)	2008-10-15	Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität